Chugai Pharmaceutical Co., Ltd. (CUP0) - Total Liabilities
Based on the latest financial reports, Chugai Pharmaceutical Co., Ltd. (CUP0) has total liabilities worth €442.86 Billion EUR as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chugai Pharmaceutical Co., Ltd. - Total Liabilities Trend (2021–2025)
This chart illustrates how Chugai Pharmaceutical Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chugai Pharmaceutical Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Chugai Pharmaceutical Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Royal Caribbean Cruises Ltd
NYSE:RCL
|
USA | $29.82 Billion |
|
Ecolab Inc
NYSE:ECL
|
USA | $14.14 Billion |
|
Synopsys Inc
NASDAQ:SNPS
|
USA | $16.69 Billion |
|
Schlumberger Limited
SA:SLBG34
|
Brazil | R$28.76 Billion |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
USA | $78.25 Billion |
|
Investor AB ser. B
ST:INVE-B
|
Sweden | Skr148.91 Billion |
|
Vinci S.A.
PA:DG
|
France | €102.31 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Chugai Pharmaceutical Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chugai Pharmaceutical Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chugai Pharmaceutical Co., Ltd. (2021–2025)
The table below shows the annual total liabilities of Chugai Pharmaceutical Co., Ltd. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €442.86 Billion | +44.31% |
| 2024-12-31 | €306.87 Billion | -0.03% |
| 2023-12-31 | €306.97 Billion | -31.08% |
| 2022-12-31 | €445.37 Billion | +27.00% |
| 2021-12-31 | €350.68 Billion | -- |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal … Read more